136 related articles for article (PubMed ID: 24083389)
1. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.
Zhu FG; Jiang W; Bhagat L; Wang D; Yu D; Tang JX; Kandimalla ER; La Monica N; Agrawal S
Autoimmunity; 2013 Nov; 46(7):419-28. PubMed ID: 24083389
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.
Barrat FJ; Meeker T; Chan JH; Guiducci C; Coffman RL
Eur J Immunol; 2007 Dec; 37(12):3582-6. PubMed ID: 18034431
[TBL] [Abstract][Full Text] [Related]
3. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis.
Jiang W; Zhu FG; Bhagat L; Yu D; Tang JX; Kandimalla ER; La Monica N; Agrawal S
J Invest Dermatol; 2013 Jul; 133(7):1777-84. PubMed ID: 23370539
[TBL] [Abstract][Full Text] [Related]
4. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.
Santiago-Raber ML; Dunand-Sauthier I; Wu T; Li QZ; Uematsu S; Akira S; Reith W; Mohan C; Kotzin BL; Izui S
J Autoimmun; 2010 Jun; 34(4):339-48. PubMed ID: 19944565
[TBL] [Abstract][Full Text] [Related]
5. Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice.
Chen M; Aosai F; Norose K; Mun HS; Ishikura H; Hirose S; Piao LX; Fang H; Yano A
Int Immunol; 2004 Jul; 16(7):937-46. PubMed ID: 15148287
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism.
Tran NL; Manzin-Lorenzi C; Santiago-Raber ML
Immunology; 2015 May; 145(1):60-70. PubMed ID: 25424423
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.
Christensen SR; Shupe J; Nickerson K; Kashgarian M; Flavell RA; Shlomchik MJ
Immunity; 2006 Sep; 25(3):417-28. PubMed ID: 16973389
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus.
Pawar RD; Ramanjaneyulu A; Kulkarni OP; Lech M; Segerer S; Anders HJ
J Am Soc Nephrol; 2007 Jun; 18(6):1721-31. PubMed ID: 17460144
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.
Kandimalla ER; Bhagat L; Wang D; Yu D; Sullivan T; La Monica N; Agrawal S
Nucleic Acids Res; 2013 Apr; 41(6):3947-61. PubMed ID: 23396449
[TBL] [Abstract][Full Text] [Related]
10. Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease.
Liu SD; Lee S; La Cava A; Motran CC; Hahn BH; Miceli MC
Lupus; 2011 Apr; 20(5):473-84. PubMed ID: 21335401
[TBL] [Abstract][Full Text] [Related]
11. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.
Lamphier M; Zheng W; Latz E; Spyvee M; Hansen H; Rose J; Genest M; Yang H; Shaffer C; Zhao Y; Shen Y; Liu C; Liu D; Mempel TR; Rowbottom C; Chow J; Twine NC; Yu M; Gusovsky F; Ishizaka ST
Mol Pharmacol; 2014 Mar; 85(3):429-40. PubMed ID: 24342772
[TBL] [Abstract][Full Text] [Related]
12. Gr-1(high) CD11b+ cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice.
Trigunaite A; Khan A; Der E; Song A; Varikuti S; Jørgensen TN
Arthritis Rheum; 2013 Sep; 65(9):2392-402. PubMed ID: 23754362
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus.
Lech M; Kantner C; Kulkarni OP; Ryu M; Vlasova E; Heesemann J; Anz D; Endres S; Kobayashi KS; Flavell RA; Martin J; Anders HJ
Ann Rheum Dis; 2011 Dec; 70(12):2207-17. PubMed ID: 21875872
[TBL] [Abstract][Full Text] [Related]
14. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule.
Nakajima A; Azuma M; Kodera S; Nuriya S; Terashi A; Abe M; Hirose S; Shirai T; Yagita H; Okumura K
Eur J Immunol; 1995 Nov; 25(11):3060-9. PubMed ID: 7489744
[TBL] [Abstract][Full Text] [Related]
15. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.
Summers SA; Hoi A; Steinmetz OM; O'Sullivan KM; Ooi JD; Odobasic D; Akira S; Kitching AR; Holdsworth SR
J Autoimmun; 2010 Dec; 35(4):291-8. PubMed ID: 20810248
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of TLR7 and TLR9 in murine SLE.
Santiago-Raber ML; Baudino L; Izui S
J Autoimmun; 2009; 33(3-4):231-8. PubMed ID: 19846276
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
18. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
19. Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease.
Wong M; La Cava A; Singh RP; Hahn BH
J Immunol; 2010 Dec; 185(11):6563-71. PubMed ID: 21041733
[TBL] [Abstract][Full Text] [Related]
20. Soluble human CD83 ameliorates lupus in NZB/W F1 mice.
Starke C; Steinkasserer A; Voll RE; Zinser E
Immunobiology; 2013 Nov; 218(11):1411-5. PubMed ID: 23886695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
